
RBN-2397
CAS No. 2381037-82-5
RBN-2397( —— )
Catalog No. M21754 CAS No. 2381037-82-5
RBN-2397 (0.0001-100 μM; 24 hours) inhibits cells proliferation with an IC50 value of 20 nM in NCI-H1373 lung cancer cells.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 374 | In Stock |
![]() ![]() |
10MG | 556 | In Stock |
![]() ![]() |
25MG | 887 | In Stock |
![]() ![]() |
50MG | 1197 | In Stock |
![]() ![]() |
100MG | 1611 | In Stock |
![]() ![]() |
500MG | 3231 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameRBN-2397
-
NoteResearch use only, not for human use.
-
Brief DescriptionRBN-2397 (0.0001-100 μM; 24 hours) inhibits cells proliferation with an IC50 value of 20 nM in NCI-H1373 lung cancer cells.
-
DescriptionRBN-2397 (0.0001-100 μM; 24 hours) inhibits cells proliferation with an IC50 value of 20 nM in NCI-H1373 lung cancer cells.RBN-2397 (0.4 nM-1 μM; 24 hours) shows a restoration of type I IFN response by an increase in STAT1 phosphorylation as a dose-dependent manner in NCI-H1373 human lung cancer cells.RBN-2397 (0.0001-1 μM; 24 hours) inhibits cell MARylation in a cell biochemial assay with an EC50 value of 1 nM.(In Vitro):RBN-2397 (0.0001-100 μM; 24 hours) inhibits cells proliferation with an IC50 value of 20 nM in NCI-H1373 lung cancer cells.RBN-2397 (0.4 nM-1 μM; 24 hours) shows a restoration of type I IFN response by an increase in STAT1 phosphorylation as a dose-dependent manner in NCI-H1373 human lung cancer cells.RBN-2397 (0.0001-1 μM; 24 hours) inhibits cell MARylation in a cell biochemial assay with an EC50 value of 1 nM.(In Vivo):RBN-2397 (oral administration; 3-100 mg/kg; once daily; 24-32 days) induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses in CT26 tumor-bearing BALB/c mice.RBN-2397 (oral administration; 3-100 mg/kg; once daily; 32 days) causes complete regressions at the dose 100 mg/kg and exerts a dose-dependent effects on tumor growth at dose levels of ≥30 mg/kg.The half-life (t1/2) of RBN-2397 in vivo is 325 mins.
-
In VitroRBN-2397 (0.0001-100 μM; 24 hours) inhibits cells? proliferation with an IC50 value of 20 nM in NCI-H1373 lung cancer cells.RBN-2397 (0.4 nM-1 μM; 24 hours) shows a restoration of type I IFN response by an increase in STAT1 phosphorylation as a dose-dependent manner in NCI-H1373 human lung cancer cells.RBN-2397 (0.0001-1 μM; 24 hours) inhibits cell MARylation in a cell biochemial assay with an EC50 value of 1 nM. Cell Proliferation Assay Cell Line:NCI-H1373 lung cancer cells Concentration:0.0001 μM; 0.001 μM; 0.001 μM; 0.1 μM; 1 μM; 10 μM; 100 μM Incubation Time:24 hours Result:Blocked cell proliferation. Western Blot Analysis Cell Line:NCI-H1373 lung cancer cells Concentration:0.4 nM-1 μM Incubation Time:24 hours Result:Increasedp-STAT1 protein expression.
-
In VivoRBN-2397 (oral administration; 3-100 mg/kg; once daily; 24-32 days) induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses in CT26 tumor-bearing BALB/c mice.RBN-2397 (oral administration; 3-100 mg/kg; once daily; 32 days) causes complete regressions at the dose 100 mg/kg and exerts a dose-dependent effects on tumor growth at dose levels of ≥30 mg/kg.The half-life (t1/2) of RBN-2397 in vivo is 325 mins. Animal Model:CB17 SCID mice withNCI-H1373 xenografts Dosage:3 mg/kg, 10mg/kg, 30 mg/kg, 100 mg/kg Administration:Oral administration; once daily; 24-32 days Result:Decreased tumor volume and exerted anti-tumor effects.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2381037-82-5
-
Formula Weight523.43
-
Molecular FormulaC??H??F?N?O?
-
Purity>98% (HPLC)
-
SolubilityDMSO : 250 mg/mL (477.62 mM; Need ultrasonic)
-
SMILESO=C1C(C(F)(F)F)=C(N[C@@H](C)COCCC(N2CCN(C3=NC=C(C(F)(F)F)C=N3)CC2)=O)C=NN1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Melissa Vasbinder, et al. RBN-2397: A First-in-Class PARP7 Inhibitor Targeting a Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways.
molnova catalog



related products
-
Talazoparib
Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.58 nM.
-
D-Arabinose
Inexpensive starting material for chiral synthesis.
-
MK-4827
MK-4827 (Niraparib, MK4827) is a highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2.